Gastroesophageal Reflux Disease Market Forecasts to 2030 – Global Analysis By Product (Tablet, Capsule, Suspension, Solution and Other Products), Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antag

Gastroesophageal Reflux Disease Market Forecasts to 2030 – Global Analysis By Product (Tablet, Capsule, Suspension, Solution and Other Products), Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication and Other Drug Types), Diagnosis (Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry and Other Diagnosis), Route of Administration, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Gastroesophageal Reflux Disease Market is accounted for $5.37 billion in 2023 and is expected to reach $6.93 billion by 2030 growing at a CAGR of 3.7% during the forecast period. Heartburn is a burning sensation that is brought on by a condition called gastroesophageal reflux disease (GERD). Moreover, reflux, a backward movement that produces a burning sensation in the lower part of the esophagus, is what happens when the stomach's hydrochloric acid-containing contents travel upward again.

According to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50.

Market Dynamics:

Driver:

New approaches to drug development

The pharmaceutical industry's dedication to GERD research and development has resulted in the development of increasingly safe and effective drugs for the condition's management. Additionally, innovations include not only the creation of new drug formulations but also personalized medicine strategies that customize treatments for specific patients based on lifestyle and genetic factors. By addressing GERD-related complications like Barrett's esophagus, esophageal cancer, and respiratory disorders, these innovations offer a more all-encompassing approach to treatment and prevention.

Restraint:

Overuse and adverse reactions to medication

Proton pump inhibitors (PPIs), one type of medication used to treat GERD should not be used for an extended period of time due to the risk of side effects. PPIs are useful, but they raise questions about kidney function, bone health, and nutrient malabsorption. Furthermore, it can be difficult for patients and healthcare professionals to manage these side effects and strike a balance between short-term symptom relief and long-term health.

Opportunity:

Technologies for diagnostic instruments

An important opportunity for the early and precise diagnosis of GERD is provided by continuous improvements in diagnostic tools, such as high-resolution esophageal manometry, ambulatory pH monitoring, and sophisticated endoscopy methods like confocal laser endomicroscopy. These instruments facilitate the evaluation of the degree of esophageal injury, the detection of complications such as Barrett's esophagus, and the choice of the best course of action for selected patients. Moreover, patients can receive more effective and individualized treatments aimed at symptom relief and long-term problem prevention with an earlier and more accurate diagnosis.

Threat:

Tolerance and resistance to medication

Proton pump inhibitors (PPIs) in particular should not be used for extended periods of time, as some patients may develop drug resistance and tolerance. It is possible that these drugs will lose their effectiveness with time and that higher doses or other medications will be necessary. Additionally, patients who seek stronger medications or more therapies to manage their symptoms may become resistant to their prescribed medications, which can make treatment decisions more difficult and raise medical expenses.

Covid-19 Impact:

Gastroesophageal reflux disease (GERD) and the global healthcare market have both been significantly impacted by the COVID-19 pandemic. Significant changes in patient behavior and healthcare delivery were also brought about by the pandemic, even though it first caused disruptions to healthcare services and supply chains, including the manufacture and distribution of GERD medications and medical devices. Furthermore, lockdowns and other social distancing measures led to a spike in the use of telemedicine and remote monitoring for GERD patients, which allowed for continued care while lowering the risk of contracting the virus.

The Capsule segment is expected to be the largest during the forecast period

It is projected that the capsule segment will command the largest market share for gastroesophageal reflux disease. Because of their adaptability, simplicity in production, and patient-friendly qualities, capsules are widely used. They offer a practical and efficient means of delivering a variety of pharmaceutical formulations, such as liquid, semi-solid, or solid substances. Patients of all ages prefer capsules because they provide accurate dosing and ease of swallowing, making them a popular choice for both prescription and over-the-counter medications. Furthermore, capsules can be used for a wide range of therapeutic applications, including the formulation of specialty drugs, vitamins, herbal supplements, and antibiotics.

The Homecare segment is expected to have the highest CAGR during the forecast period

Over the course of the projection period, the homecare segment has shown the highest CAGR. The need for homecare services has increased significantly as a result of a number of factors, such as the aging population, the desire for individualized care in comfortable settings, and developments in telehealth and medical technology. Moreover, homecare services are appealing for patients who need ongoing care, monitoring, or rehabilitation while remaining in their own homes because they cover a wide range of medical and non-medical assistance. Depending on the patient's needs, these services can include physical therapy, medication management, nursing care, and even complex medical procedures.

Region with largest share:

The region of North America is projected to possess the largest market share. The region is well-known for a number of reasons, including a strong pharmaceutical and medical device industry, a large healthcare infrastructure, and high healthcare spending. Particularly in terms of drug development and innovation, the pharmaceutical industry in the United States is substantial. Another factor in North America's dominance is the abundance of internationally recognized research centers and healthcare facilities. Additionally, the North American healthcare market is still changing, with an increasing emphasis on value-based care, innovative therapies, and medical technology.

Region with highest CAGR:

The market's highest CAGR is being experienced by the Asia-Pacific region. Numerous factors, such as the fast-growing population, growing urbanization, increased awareness of healthcare, and significant economic development in nations like China and India, can be credited for this robust growth. These countries are seeing large investments in pharmaceuticals, medical technology, and healthcare infrastructure. Furthermore, the Asia-Pacific area is becoming known as a center for clinical trials and research, drawing pharmaceutical and medical device manufacturers from throughout the world.

Key players in the market

Some of the key players in Gastroesophageal Reflux Disease market include Medtronic Plc, Takeda Pharmaceutical Company Limited., Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Olympus Corporation, TWi Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., SRS Life Sciences, Reckitt Benckiser Group PLC, Zydus Group, AstraZeneca PLC, Camber Pharmaceuticals, Inc., Pfizer Inc., Teva Pharmaceuticals Industries Limited., Aurobindo Pharma, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc. and SFJ Pharmaceuticals.

Key Developments:

In May 2023, Medtronic plc, a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor, is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

In January 2023, Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter’s fruquintinib. Under the deal terms, the company will have an exclusive global licence for the development and commercialisation of fruquintinib for all indications and territories outside of mainland China, Macau, and Hong Kong.

Products Covered:
• Tablet
• Capsule
• Suspension
• Solution
• Other Products

Drug Types Covered:
• Antacids
• Proton Pump Inhibitors
• H2 Receptor Blocker
• Pro Kinetic Agents
• Dopamine Receptor Antagonist
• EndoCinch
• Stretta
• EsophyX
• Transoral Incisionless
• Fundoplication
• Other Drug Types

Diagnosis Covered:
• Upper Endoscopy
• Ambulatory Acid (pH) Probe Test
• Esophageal Manometry
• Other Diagnosis

Route of Administrations Covered:
• Oral
• Parental

Distribution Channels Covered:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

End Users Covered:
• Hospital
• Homecare
• Specialty Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances